LKB1ness Dictates ERK Inhibitors Response in NSCLC

Affiliations

¹ Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
² Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. Electronic address: massimo.broggini@marionegri.it.

Free article

Comment

Elisa Caiola et al. J Thorac Oncol. 2020 Apr.

Free article

. 2020 Apr;15(4):e59.

doi: 10.1016/j.jtho.2020.02.006.

¹ Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
² Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. Electronic address: massimo.broggini@marionegri.it.

No abstract available

Comment on

LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors.
Caiola E, Iezzi A, Tomanelli M, Bonaldi E, Scagliotti A, Colombo M, Guffanti F, Micotti E, Garassino MC, Minoli L, Scanziani E, Broggini M, Marabese M. Caiola E, et al. J Thorac Oncol. 2020 Mar;15(3):360-370. doi: 10.1016/j.jtho.2019.10.009. Epub 2019 Oct 18. J Thorac Oncol. 2020. PMID: 31634668
Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in RAS-Mutant Lung Cancer.
Yang H. Yang H. J Thorac Oncol. 2020 Apr;15(4):e58-59. doi: 10.1016/j.jtho.2020.01.004. J Thorac Oncol. 2020. PMID: 32216949 No abstract available.